NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 77 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q2 2013. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2015 | $4,000 | -81.0% | 2,473 | -77.9% | 0.00% | – |
| Q4 2014 | $21,000 | -97.1% | 11,175 | -96.8% | 0.00% | -100.0% |
| Q4 2013 | $733,000 | -79.8% | 354,200 | -74.1% | 0.01% | -85.7% |
| Q3 2013 | $3,620,000 | +44.1% | 1,366,100 | +45.2% | 0.04% | +29.6% |
| Q2 2013 | $2,512,000 | – | 941,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sowell Financial Services LLC | 1,507,457 | $593,000 | 0.17% |
| Harel Insurance Investments & Financial Services Ltd. | 780,000 | $398,000 | 0.03% |
| Spark Investment Management LLC | 353,400 | $180,000 | 0.01% |
| LifePlan Financial Group, Inc | 28,810 | $15,000 | 0.01% |
| Greenwich Wealth Management LLC | 60,066 | $31,000 | 0.01% |
| SHINE INVESTMENT ADVISORY SERVICES INC | 19,608 | $10,000 | 0.01% |
| Virtu KCG Holdings LLC | 336,414 | $172,000 | 0.01% |
| LYNCH & ASSOCIATES/IN | 18,000 | $9,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 649,880 | $331,000 | 0.00% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 377,875 | $193,000 | 0.00% |